Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 16/20 | 0.50 |
| ▸ | FGFR1 | P11362 | 15/20 | 0.50 |
| ▸ | EGFR | P00533 | 2/20 | 0.40 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.40 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.40 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.40 |
| ▸ | WEE1 | P30291 | 3/20 | 0.35 |
| ▸ | CDC7 | O00311 | 1/20 | 0.35 |
| ▸ | CDK2 | P24941 | 1/20 | 0.35 |
| ▸ | ABL1 | P00519 | 2/20 | 0.34 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.34 |
| ▸ | KIT | P10721 | 2/20 | 0.34 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.34 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5061776 | 0.92 | FGFR1 (0.48) | SRCFGFR1EGFRFGFR2FGFR4 | |
| SCHEMBL4427123 | 0.89 | FGFR1 (0.46) | SRCFGFR1EGFRFGFR2FGFR4 | |
| SCHEMBL15000178 | 0.88 | FGFR1 (0.46) | SRCFGFR1EGFRFGFR2FGFR4 | |
| SCHEMBL4566352 | 0.86 | FGFR1 (0.61) | SRCFGFR1 | |
| SCHEMBL14999750 | 0.85 | BTK (0.42) | SRCFGFR1EGFRFGFR2FGFR4 | |
| SCHEMBL5061835 | 0.85 | BTK (0.48) | SRCKITPDGFRA | |
| SCHEMBL5061438 | 0.82 | FGFR1 (0.49) | SRCFGFR1EGFRFGFR2FGFR4 | |
| SCHEMBL29800744 | 0.81 | BTK (0.38) | SRCFGFR1FGFR4 | |
| SCHEMBL20852492 | 0.81 | BTK (0.38) | SRCFGFR1FGFR4 | |
| SCHEMBL4566795 | 0.81 | SRC (0.55) | SRCFGFR1EGFRFGFR2FGFR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE48731-E1 | Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases | DECIPHERA PHARMACEUTICALS, LLC (US) | 2021-09-14 | — | — | US | disclosed |
| EP-3722296-A2 | DIHYDRONAPHTHYRIDINES AND RELATED COMPOUNDS USEFUL AS KINASE INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISEASES | Deciphera Pharmaceuticals, LLC (US) | 2020-10-14 | — | — | EP | disclosed |
| EP-3366293-B1 | DIHYDRONAPHTHYRIDINES AND RELATED COMPOUNDS USEFUL AS KINASE INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISEASES | DECIPHERA PHARMACEUTICALS LLC (US) | 2020-03-11 | — | — | EP | disclosed |
| EP-3366293-A1 | DIHYDRONAPHTHYRIDINES AND RELATED COMPOUNDS USEFUL AS KINASE INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISEASES | Deciphera Pharmaceuticals, LLC (US) | 2018-08-29 | — | — | EP | disclosed |
| EP-2858646-B1 | DIHYDRONAPHTHYRIDINES AND RELATED COMPOUNDS USEFUL AS KINASE INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISEASES | DECIPHERA PHARMACEUTICALS LLC (US) | 2017-12-20 | — | — | EP | disclosed |
| US-20150320759-A1 | DIHYDRONAPHTHYRIDINES AND RELATED COMPOUNDS USEFUL AS KINASE INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISEASES | DECIPHERA PHARMACEUTICALS, LLC | 2015-11-12 | — | — | US | disclosed |
| EP-2858646-A1 | DIHYDRONAPHTHYRIDINES AND RELATED COMPOUNDS USEFUL AS KINASE INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISEASES | Flynn, Daniel L. (US) | 2015-04-15 | — | — | EP | disclosed |
| US-8940756-B2 | Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases | DECIPHERA PHARMACEUTICALS, LLC | 2015-01-27 | — | — | US | disclosed |
| US-20140088075-A1 | DIHYDRONAPHTHYRIDINES AND RELATED COMPOUNDS USEFUL AS KINASE INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISEASES | DECIPHERA PHARMACEUTICALS, INC. (US) | 2014-03-27 | — | — | US | disclosed |
| WO-2013184119-A1 | DIHYDRONAPHTHYRIDINES AND RELATED COMPOUNDS USEFUL AS KINASE INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISEASES | FLYNN DANIEL L (US) | 2013-12-12 | — | — | WO | disclosed |
| US-8461179-B1 | Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases | DECIPHERA PHARMACEUTICALS, LLC (US) | 2013-06-11 | — | — | US | disclosed |
| US-20120289540-A1 | KINASE INHIBITORS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | DECIPHERA PHARMACEUTICALS, LLC (US) | 2012-11-15 | — | — | US | disclosed |
| US-8188113-B2 | For example, 1-(5-(2-amino-8-methyl-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidin-6-yl)-2-fluorophenyl)-3-(3-tert-butyl-1-phenyl-1H-pyrazol-5-yl)urea; for treatment of mammalian cancers and inflammatory diseases including rheumatoid arthritis, retinopathies | DECIPHERA PHARMACEUTICALS, INC. (US) | 2012-05-29 | — | — | US | disclosed |
| EP-2063897-A2 | KINASE INHIBITORS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | Deciphera Pharmaceuticals, LLC. (US) | 2009-06-03 | — | — | EP | disclosed |
| US-20080114006-A1 | Kinase inhibitors useful for the treatment of proliferative diseases | DECIPHERA PARMACEUTICALS, LLC (US) | 2008-05-15 | — | — | US | disclosed |
| WO-2008034008-A2 | KINASE INHIBITORS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | DECIPHERA PHARMACEUTICALS, LLC. (US) | 2008-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150320759-A1 | DIHYDRONAPHTHYRIDINES AND RELATED COMPOUNDS USEFUL AS KINASE INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISEASES | NME1, DCK, NME2 | SRC 715/4885FGFR1 376/4885EGFR 797/4885 |
| US-20120289540-A1 | KINASE INHIBITORS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | BRAF, PRKDC, RAF1 | SRC 417/4885FGFR1 577/4885EGFR 349/4885 |
| US-20140088075-A1 | DIHYDRONAPHTHYRIDINES AND RELATED COMPOUNDS USEFUL AS KINASE INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISEASES | NME1, DCK, NME2 | SRC 715/4885FGFR1 376/4885EGFR 797/4885 |
| US-20080114006-A1 | Kinase inhibitors useful for the treatment of proliferative diseases | BRAF, PRKDC, RAF1 | SRC 417/4885FGFR1 577/4885EGFR 349/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.